Orientations
MCV 5-dose 2-Pager
This two-page brief summarizes the rationale, evidence, and implementation considerations for transitioning from 10-dose to 5-dose measles-containing vaccine (MCV) vials for routine immunization. Designed for EPI managers, NITAGs, and immunization partners, it outlines how fewer-dose vials can reduce missed opportunities for vaccination, improve coverage, and support routine immunization strengthening. The brief highlights global evidence and country experiences, key considerations for assessing country fit, funding and implementation implications, and practical next steps for planning a switch to the 5-dose presentation.
Auteurs
Langues
- Anglais
Année de publication
2026
Type
Catégories
Mots-clés
MCV5 PHASE 1
Cette ressource apparaît sur le Thème suivant:
Cette ressource est incluse dans le tableau suivant:
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Experiences with the MCV 5-dose Switch from Africa’s EPI | UNICEF | 2024 | Case study | Anglais |
| MCV 5-dose 2-Pager | Linksbridge | 2026 | Guidance | Anglais |
| MCV 5-dose Option Overview | Linksbridge | 2026 | Guidance | Anglais |
| MCV 5-dose Research and Resources | Linksbridge | 2022 | Report | Anglais |
| Measles and Measles-Rubella (MR) Vaccine Five-Dose Vial Presentation - Fact Sheet 2022 - 2023 | UNICEF, World Health Organization (WHO) | 2022 | Guidance | Anglais |
